In vitro analysis by Veluchamy et al. [129] provided a rationale to enhance cetuximab efficacy through a combination with NK-cell therapy for metastatic CRC patients, harboring K-RAS and B-RAF mutation. This evidence concerns the gene BRAF and colorectal carcinoma.